MCMariana Creciun

Mariana Creciun

*This is an algorithmically generated author record based on publicly available information.

Mariana Creciun has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sindromul MOSH – o nouă viziune a hipogonadismului dobândit

    by Victoria Ghenciu, Arian Iurii, Ion Dumbraveanu, Mariana Creciun, Emil Ceban

    Functional male hypogonadism in association with obesity has recently been defined as secondary obesity-induced hypogonadism – MOSH syndrome. Сlinical manifestations are explained by two important mechanisms: testosterone deficiency and excess adipose tissue. Synthesis of 50 articles predominantly of the last 10 years from databases: Google Scholar, PubMed, Research Gate, Wiley Online Library, Health Data Science using keywords – „MOSH”, „hypogonadism”, „obesity”, „male sex-reproductive dysfunction”, „infertility”. The prevalence of MOSH in the general population is 45% and correlates positively with the degree of obesity. Multifactorial pathogenetic mechanisms include lipotoxicity, suppression of the hypothalamic-pituitary-gonadal axis, leptinresistance, hyperestrogenemia, oxidative stress, proinflammatory status, metabolic insulinoresistance and endotoxemia, sleep apnea, genetic and epigenetic changes, etc, with major impact on male sexual-reproductive health. Treatment strategy includes decrease in body mass, which can relieve the symptoms of androgen deficiency, improve metabolic profile and fertility. MOSH is a subtype of functional hypogonadism with reversible potential with substantial weight loss.

  • Open Access

    Hipogonadismul bărbatului în vârstă. Repere de diagnostic și tratament

    by Ion Dumbraveanu, Iurii Arian, Victoria Ghenciu, Mariana Creciun, Emil Ceban

    Late-onset hypogonadism (LOH) is the most controversial form of hypogonadism and an unsolved problem. Its prevalence is unknown, it is estimated as being at least 1 in 5 men after 40 years, and about 80% of those with comorbidities may have hypogonadism. LOH does not have age-defined criteria and may be included in its start-out and developing mechanisms elements of primary hypogonadism due to insufficient testicular function and secondary. When preparing this article, the reviews of 40 analytical studies and international guidelines of the European Academy of Andrology and the Societies of Endocrinology and Urology were consulted. This type of hypogonadism is dependent on the age and men’s health status. Decreased testosterone levels can be the result of chronic disease, diabetes, organ failure, or obesity. Or because of the presence of chronic systemic inflammation. Older patients with signs of testosterone deficiency need an individual approach to establish the presence of a reversible/ functional form of hypogonadism that can be ameliorated with other remedies than testosterone replacement therapy. After clinical and biochemical confirmation of hypogonadism, testosterone treatment recommended recommended only with an evaluation of potential benefits and risks.


  • Open Access

    Provocări actuale în diagnosticul și tratamentul deficitului de testosteron la bărbații de vârstă reproductivă

    by Iurii Arian, Ion Dumbraveanu, Victoria Ghenciu, Alan Bogdanov, Mariana Creciun, Emil Ceban

    Currently, an increasing number of young and middle-aged men are seeking treatment for symptoms related to low testosterone levels, which include depression, chronic fatigue, low libido, erectile dysfunction and/or infertility. In situations where conceiving a child is not a short- or medium-term goal, the preservation of reproductive function needs to be considered in the context of the treatment offered. Testosterone deficiency is often of unknown origin especially in men of reproductive age, and the choice of treatment method becomes even more difficult, in the context where the scientific evidence and degree of recommendation of various treatments is weak. Literature review was performed using major databases including PubMed, Hinari, SpringerLink and Scopus (Elsevier). One third of infertile men under the age of 50 were found to be hypogonadal. Correlation of spermogram result with testosterone level identified deficiency in 16.7% of men with obstructive azoospermia, 45% of men with non-obstructive azoospermia, 42.9% of men with oligozoospermia and/or asthenozoospermia and 35.3% of men with normal sperm parameters. Testosterone replacement therapy, although effective in addressing most symptoms of hypogonadism, has negative effects on testicular function. Counseling should include a thorough discussion of risks and benefits with an emphasis on spermatogenesis suppression for men of reproductive age who wish to maintain their reproductive potential.

  • Open Access

    Efectele substanțelor auxiliare folosite în dopaj asupra funcţiei sexual-reproductive masculine

    by Mariana Creciun, Victoria Ghenciu, Iurii Arian, Constantin Tataru, Ion Dumbraveanu

    Using pharmacological substances to enhance athletic performance, known as doping, is widespread in sports and bodybuilding. Doping involves substances such as anabolic steroids, selective androgen receptor modulators, peptide hormones, beta-2 adrenergic agonists, and other auxiliary substances that temporarily enhance physical performance. Although perceived as safer alternatives to traditional steroids, they pose significant health risks, including on male reproductive function. The literature was reviewed using electronic databases such as PubMed, Scopus, and Google Scholar, Out of 296 articles published until 2024, 30 were included in the study providing data on the effects of these substances on sexual-reproductive function. Although SARMs do not have adverse effects like steroids, their excessive use can suppress endogenous testosterone production, affecting spermatogenesis. Peptide hormones and beta-2 adrenergic agonists can disrupt hormonal balance, affecting the hypothalamic-pituitary-gonadal (HPG) axis, suppressing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Myostatin inhibitors and excessive consumption of amino acid derivatives can cause hormonal imbalances and oxidative stress, affecting the quality of seminal material. Auxiliary substances with anabolic effects used in doping can have significant adverse effects on male reproductive health, such as suppression of the HPG axis, decreased testosterone, and impaired spermatogenesis. Further studies are needed to understand the exact mechanisms and long-term impact of these substances on reproductive health.


  • Diagnostic evaluation and therapeutic management of the male in the infertile couple

    by Ion Dumbraveanu, Iurii Arian, Victoria Ghenciu, Mariana Creciun, Andrei Bradu, Mihaela Ivanov, Emil Ceban

    About 15-20 % couples have no children or have not enough than they want. About 50 % of the causes infertility in the couple its related to the male etiological factor. Only 60 -70 % of the causes of male infertility are known, 40 % is considered idiopathic or unexplained. The diagnostic and therapeutic management of the male infertility is permamently addapted to new scientific discoveries. The purpose of the article is a analaisys of the methods of diagnostic and treatment of male infertility through the the scientiphic discovery acording to the data providen in international guidelines. Male infertility has multiple etiological factors (urology, endocrine, genetic) and requires a adequate evaluation, which is not limited to spermogram analasys. In case of infertile couple, the male must be examined totaly not only to elucidate and treat the etiological factors involved, but to diagnose other concomitent other than urologic disorder with potential consequences for the futher quality and duration of life.